Niraparib for Soft Tissue Sarcoma
This trial will test the effectiveness of niraparib against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. It will also study the safety and side-effects of niraparib.
- Soft Tissue Sarcoma
- Uterine Sarcoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has Niraparib been cleared by the FDA?
"Since this is a phase 2 trial, meaning that while there is some evidence of safety, there is none for efficacy, we have rated Niraparib as a 2 in terms of safety."
What is the projected scope of this clinical trial in terms of participants?
"The information available on clinicaltrials.gov seems to suggest that this study is still open to enrolling patients. This trial was originally posted on August 23rd, 2022 and was last updated September 7th, of the same year. The researchers conducting this study hope to recruit 32 participants from 7 different locations."
Are there any participants still needed for this research?
"That is correct, the online information shows that the trial is open and looking for volunteers. The listing went up on 8/23/2022 and was updated most recently on 9/7/2022. They need 32 people in total and have 7 different centres where patients can be recruited from."
In how many different areas is this investigation being conducted today?
"Currently, there are 7 active sites for this research study. They are situated in Basking Ridge, Middletown and New York amongst other places. To limit the amount of travel needed, please choose the site closest to your location."